ecallantide: Clinical Trials

6 trials of ecallantide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated, 1 withdrawn. 6 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Completed 3, Terminated 2, Withdrawn 1
Phase 31Withdrawn 1

Follow ecallantide: new trials by email Literature Review of ecallantide trials Research Report on ecallantide

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema
ecallantide - Hereditary Angioedema (HAE)
Phase 2 / Phase 3WithdrawnShire2012-06-012021-05-18
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
ecallantide 60 mg, ecallantide 30 mg, ecallantide 10 mg - ACE Inhibitor Induced Angioedema
Phase 2TerminatedShire792011-06-012021-06-11
Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery
Ecallantide, Cyklokapron(R) - Bloodloss, Surgical Procedures, Operative
Phase 2CompletedCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)2432009-06-012015-08-10
A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume
ecallantide, placebo - Bloodloss, Surgical Procedures, Operative
Phase 2CompletedCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)2762009-03-012015-08-11
Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement
Ecallantide, Placebo - Blood Loss, Surgical
Phase 2TerminatedCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)752007-05-012019-06-25
EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema
DX-88 (ecallantide) - Hereditary Angioedema (HAE)
Phase 2CompletedShire772003-11-012021-05-18

Conditions studied

Angioedemas, Hereditary (2)  ·  Blood Loss, Surgical (1)

Sponsors

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (3)  ·  Shire (3)

Countries

United States (4)  ·  Canada (1)  ·  Germany (1)  ·  Poland (1)

Top investigators

Alistair Wheeler, MD, MFPM (2)  ·  Andrew L Sternlicht, MD (1)

Results publications

PMID 21724197, PMID 23878046, PMID 24712435, PMID 25182544